CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 26 enrolled
Drug / intervention
Metvix® +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02373371
NCT02373371Phase 3Completed
CompareCT.gov

Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses

University Hospital, Limoges·interventional·Posted Feb 27, 2015·Updated Jul 29, 2025

In Brief

A Phase 3 clinical trial evaluating Metvix®, Photodynamic Therapy Blue light, and 1 other intervention for Actinic Keratoses. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The main objective of this study is to compare efficacy and safety of Metvix® natural daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy in subjects with mild actinic keratoses (intra-individual comparison)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratoses
CountriesFrance
CollaboratorsGalderma R&D

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 27, 2015
Enrollment StartMar 25, 2015
Primary CompletionNov 22, 2016
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.3 years ago

Interventions

Metvix®drug

Photodynamic Therapy Blue lightprocedure

Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug

Photodynamic Therapy Daylightprocedure

Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug